40



# **GM-CSF**, human recombinant

010

## Information

| Gene ID             | 1437   |  |  |
|---------------------|--|--|--|
| Accession #         | P04141   |  |  |
| Alternate Names     | Granulocyte/Macrophage Colony-Stimulating Factor, CSF-2, MGI-1GM, Pluripoietin- $\alpha$   |  |  |
| Source              | Escherichia coli.  |  |  |
| M.Wt                | Approximately 14.5 kDa, a single non-glycosylated polypeptide chain containin 127 amino acids.   |  |  |
| AA Sequence         | APARSPSPST QPWEHVNAIQ EARRLLNLSR DTAAEMNETV EVISEMFDLQ<br>EPTCLQTRLE LYKQGLRGSL TKLKGPLTMM ASHYKQHCPP TPETSCATQI<br>ITFESFKENL KDFLLVIPFD CWEPVQE  |  |  |
| Appearance S        | Sterile Filtered White lyophilized (freeze-dried) powder.  |  |  |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.  |  |  |
|                     | - 3 years from date of receipt, -20 to -70 °C as supplied.   |  |  |
|                     | <ul> <li>- 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>- 3 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>  |  |  |
| Formulation         | Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4.   |  |  |
| Reconstitution      | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |  |  |
| Biological Activity | Fully biologically active when compared to standard. The ED $_{50}$ as determined by a cell proliferation assay using human TF-1 cells is less than 0.1 ng/ml, corresponding to a specific activity of > 1.0 × $10^7$ IU/mg.   |  |  |
| Shipping Condition  | Gel pack.  |  |  |
| Handling            | Centrifuge the vial prior to opening.  |  |  |
| Usage               | For Research Use Only! Not to be used in humans.   |  |  |

# ■ Components and Storage

| Components                | 5 µg | 100 µg | 500 µg |
|---------------------------|------|--------|--------|
| GM-CSF, human recombinant | 5 µg | 100 µg | 500 µg |

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

### **Quality Control**

| Purity    | > 98 % by SDS-PAGE and HPLC analyses.                         |
|-----------|---|
| Endotoxin | Less than 1.0 EU/μg of rHuGM-CSF as determined by LAL method. |

## **Description**

Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) is secreted by a number of different cell types (including activated T cells, B cells, macrophages, mast cells, endothelial cells and fibroblasts) in response to cytokine or immune and inflammatory stimulation. It was initially characterized as a growth factor that can support the in vitro colony formation of granulocyte-macrophage progenitors and has functions of stimulates the growth and differentiation of hematopoietic precursor cells from various lineages. GM-CSF has also been reported to have a functional role on non-hematopoietic cells and can induce human endothelial cells to migrate and proliferate. Additionally, it can stimulate the proliferation of a number of tumor cell lines, including osteogenic sarcoma, carcinoma and adenocarcinoma cell lines. Human GM-CSF shares 54 % sequences identity with mouse GM-CSF, but has no biological effects across species. GM-CSF is used as a medication to stimulate the production of white blood cells following chemotherapy and has also recently been evaluated in clinical trials for its potential as a vaccine adjuvant in HIV-infected patients.

- Wang JM, Chen ZG, Colotta F, et al. 1988. Behring Inst Mitt: 270-3.
   1989. N Engl 1882 1.7
- 2. 1989. N Engl J Med, 320: 253-4.
- 3. Nissen-Druey C. 1989. Nouv Rev Fr Hematol, 31: 99-101.
- 4. Eager RandNemunaitis J. 2005. Mol Ther, 12: 18-27.
- 5. Tran T, Fernandes DJ, Schuliga M, et al. 2005. Br J Pharmacol, 145: 123-31.



7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

